Invesco Dorsey Wright Healthcare Momentum ETF
Limited financial coverage for PTH.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Range $53 – $53
Price Chart
About the company
The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) is structured to mirror the performance of the Dorsey Wright Healthcare Technical Leaders Index. This exchange-traded fund typically allocates a minimum of 90% of its total assets to the equities found within this benchmark index. The Index itself is specifically engineered to identify healthcare companies that demonstrate strong "relative strength," which indicates significant momentum.
- IPO
- 2006
- HQ
- Downers Grove, IL, US
Get TickerSpark's AI analysis on PTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $144.82M
- Div Yield
- 2.46%
- 52W High
- $64.10
- 52W Low
- $38.98
- 50D MA
- $58.02
- 200D MA
- $52.06
- Beta
- 0.97
- RSI (14)
- 59
- Avg Volume
- 51.75K
No earnings-call transcripts are available for PTH yet.
- Free Float
- 0.0%
- Shares Outstanding
- 2.33M
- Float Shares
- 0
of shares held by institutions
65 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Comerica Bank | 1.43K | 0 |
| Cwm, LLC | 529 | ▲ 184 |
Our PTH coverage
Recent articles, reports, and earnings notes.
No research on PTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTH report →Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
globenewswire.com · Aug 4
Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)?
zacks.com · Jul 27
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
globenewswire.com · Jun 16
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
globenewswire.com · Jun 13
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
globenewswire.com · Jun 11
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
businesswire.com · Jun 8
Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
globenewswire.com · May 28
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
globenewswire.com · Apr 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.